Label Changes for:

Zemplar (Paricalcitol) Injection

April 2011

Changes have been made to the WARNINGS, PRECAUTIONS and ADVERSE REACTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – April 2011

 

WARNINGS

  • Chronic hypercalcemia can lead...
  • Prescription-based doses of vitamin D...
  • Aluminum-containing preparations...
Drug Interactions
  • Specific interaction studies were...
  • ...care should be taken while paricalcitol is...

 

ADVERSE REACTIONS

Other Adverse Reactions Observed...
  • Multiple changes to section
Adverse Events During Post-Marketing Experience
  • ...allergic reactions, such as...have been reported
  • Changes to Overdosage section
 
 
Hide
(web2)